Neogen Corporation operates in food safety diagnostics with significant international revenue exposure, but declining top-line growth, weak quality scores, and a high concentration in a single product segment create structural headwinds that outweigh its favorable momentum setup.
Thesis pillars
- Revenue Decline Quality Floor→Stable
- Food Safety Segment Concentration↓Deteriorating
- Earnings Consistency Mixed↑Improving
- +1 more pillar — see the Why tab for full reasoning
Neogen Corporation (NEOG) Stock Analysis
Breakout setup
Healthcare · Medical Devices
Sell if holding. Engine safety override at $11.55: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Elevated put/call ratio: 2.00; Below-average business quality.
Neogen develops, manufactures, and markets diagnostic test kits and related products for food and animal safety through two segments: Food Safety, which generated 71.3% of fiscal 2025 revenue, and Animal Safety, which generated the remaining 28.7%. Sales outside the U.S.... Read more
Sell if holding. Engine safety override at $11.55: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Elevated put/call ratio: 2.00; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 69, MACD bullish. Score 4.7/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 57d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Neogen Corporation
About Neogen Corporation
Neogen Corporation's Food Safety segment represented 71.3% of total revenues in fiscal year 2025 (ended May 31, 2025), selling diagnostic test kits for pathogen detection, allergen testing, and food quality analysis to processors, grain elevators, and regulatory agencies globally. The Animal Safety segment added 28.7% of revenues through veterinary instruments, pharmaceuticals, genomics services, and rodent control products. International customers in more than 100 countries contributed 50.2% of total revenues in fiscal 2025, with no individual foreign country exceeding 10%.
Neogen earns revenue primarily from consumable, single-use immunoassay and nucleic acid test kits carrying royalties on licensed technology at typical rates of 2% to 10% of product revenues, plus culture media, genomics genotyping services from six global labs, and veterinary pharmaceuticals including the USDA-approved BotVax B vaccine. Distribution reaches customers through a direct sales force, specialized distributors, and subsidiaries in 28 countries. The September 2022 Reverse Morris Trust combination with 3M's Food Safety Division roughly doubled scale by adding Petrifilm plate systems and Clean-Trace ATP sanitation products, though integration challenges contributed to impairment charges in the second and fourth quarters of fiscal 2025 and management disclosed material weaknesses in internal controls over financial reporting as of May 31, 2025. In April 2025, Neogen entered into an agreement to sell its global Cleaners and Disinfectants business, trimming the Animal Safety segment.
Show full overview
Certain food safety product lines depend on a sole or single source supplier or vendor, and some of those inputs are proprietary — meaning substitutes may not be readily available if a supplier experiences disruption. The 10-K notes that a sustained interruption in raw material supply could result in significant price increases or unavailability, leading to customer losses. In March 2026, Neogen disclosed via Form 8-K that Chief Legal and Administrative Officer Amy Rocklin departed effective March 31, 2026, with no successor named, adding leadership uncertainty during a critical phase of the 3M Food Safety integration.
See also: Healthcare · Medical Devices
From Neogen Corporation's most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-08-11Recent Developments — Neogen Corporation
Latest news
- NEWS Piper Sandler Reiterates Neutral on Neogen, Raises Price Target to $13 — benzinga Aug 3, 2026 neutral
- NEWS Neogen Sees Q1 Sales $207.000M-$209.000M vs $204.710M Est — benzinga Jul 30, 2026 positive
- NEWS Neogen Q4 Adj. EPS $0.09 Beats $(0.07) Estimate, Sales $225.300M Beat $212.355M Estimate — benzinga Jul 30, 2026 positive
- NEWS Neogen Sees FY2027 Sales $880.000M-$885.000M vs $849.644M Est — benzinga Jul 30, 2026 positive
- NEWS Zoetis' Acquisition of Neogen Genomics Business Faces Regulatory Scrutiny in Australia — benzinga Jul 17, 2026 negative
Generated 2026-08-14T15:42:35Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductFood Safety segment71%10-K Item 1: 'Revenues from Neogen's Food Safety segment accounted for 71.3%, 70.9%, and 66.5% of our total revenues for fiscal years ended May 31, 2025, 2024 and 2023, respectively.'
- HIGHGeographiccustomers outside the U.S.50%10-K Item 1A: 'Sales to customers outside the U.S. accounted for 50.2%, 49.7%, and 48.4% of our total revenues for fiscal years ended May 31, 2025, 2024 and 2023, respectively.'
- HIGHSuppliersole or single source supplier10-K Item 1A: 'Certain of our food safety product lines depend on a sole or single source supplier or vendor.'
Material Events(8-K, last 90d)
- 2026-03-30Item 5.02MEDIUMChief Legal and Administrative Officer Amy Rocklin will leave the company effective March 31, 2026. No reason cited; no successor named.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Revenue shrinking — -0.1% YoY. Growth thesis broken unless recovery story develops.static
Unprofitable operations — net margin -0.9%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $11.55: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Elevated put/call ratio: 2.00; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 69, MACD bullish. Prior stop was $10.76. Score 4.7/10, moderate confidence.
Take-profit target: $12.59 (-4.5% upside). Prior stop was $10.76. Stop-loss: $10.76.
Concentration risk — Product: Food Safety segment (71.3%); Concentration risk — Geographic: customers outside the U.S. (50.2%); Target reached (-4.5% upside).
Neogen Corporation trades at a P/E of N/A (forward 30.0). TrendMatrix value score: 5.3/10. Verdict: Sell.
11 analysts cover NEOG with a consensus score of 3.9/5. Average price target: $13.
What does Neogen Corporation do?Neogen develops, manufactures, and markets diagnostic test kits and related products for food and animal safety through...
Neogen develops, manufactures, and markets diagnostic test kits and related products for food and animal safety through two segments: Food Safety, which generated 71.3% of fiscal 2025 revenue, and Animal Safety, which generated the remaining 28.7%. Sales outside the U.S. accounted for 50.2% of total revenue in fiscal 2025, and no single customer or distributor represented 10% or more of revenue.